KRAS p.G12C mutations were most predominant in NSCLC which was comprised about 11–16% of lung adenocarcinomas (p.G12C accounts for 45–50% of mutant KRAS) (Cox et al., 2014). Here, KRAS is linked to lung adenocarcinoma.